[Infostock Daily= Reporter An Hoe Hyun] Celltrion announced on the 11th that it has confirmed the safety of Phase 1 clinical trials of CT-P59, an antibody treatment for COVID-19 under development.
Celltrion received approval from the Ministry of Food and Drug Safety for the CT-P59 clinical trial plan(IND) in July and has been conducting Phase 1 clinical trials for 32 healthy subjects at Chungnam National University Hospital.
In this clinical trial, pharmacokinetics(PK) for safety and tolerability, absorption, distribution, and metabolism of CT-P59 were tested. In particular, the safety of CT-P59 was confirmed because no abnormalities occurred due to drugs in the highest dose group of cohorts.
Celltrion is currently undergoing Phase 1 clinical trials for mild patients and will enter Phase 2 and 3 large-scale global clinical trials based on the results and animal clinical results. Currently, it have completed clinical applications in seven countries including Korea.
In addition, the company plans to complete the development of the treatment by the first half of next year through clinical trials of a total of 3,000 people, including the implementation of preventive clinical trials for those in close contact within this year.
Reporter An Hoe Hyun ahh@infostock.co.kr
